Skip to main content
. Author manuscript; available in PMC: 2021 Jan 10.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2019 Sep 14;96:109761. doi: 10.1016/j.pnpbp.2019.109761

Fig.2.

Fig.2.

Carry-over effects of Ly225.910 (0.1mg Kg−1) on the two-trial elevated plus-maze performance. Anxiety-like indices are the following: (a, b) Percent of time in open arms (OAT) and (c, d). Percent of entries into open arms (OAE). Results are displayed as mean ± SEM. * p < 0.05, ** p < 0.01, compared with vehicle-treated counterpart, # # p < compared to the same group on test (two-way (Treatment x Injection) repeated ANOVA followed by t-test analysis, N = 12–25).

HHS Vulnerability Disclosure